Bridging molecular insights (e.g., hypoxia-HIF-1α-MMP-2 axis) with innovations like gene editing is essential to curb myopia progression, necessitating prioritized research on multiple pathways interaction and translational trials to advance precision ocular therapies. Here, MMP2 is linked to myopia.